Pcn93 - Economic Modeling for the Us of Intravenous vs Subcutaneous Rituximab in Non-Hodgkin’s Lymphoma Treated With R-Chop
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.175
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV